LG Chem 
Welcome,         Profile    Billing    Logout  
 40 Products   109 Diseases   40 Products   37 Trials   1900 News 


«12...891011121314151617181920»
  • ||||||||||  Xtandi (enzalutamide capsule) / Pfizer, Astellas, Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
    Trial completion date, Trial primary completion date, Metastases:  Tivozanib + Enzalutamide in Adv Prostate Cancer (clinicaltrials.gov) -  Jun 25, 2019   
    P2,  N=5, Active, not recruiting, 
    1604-138-758). Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2019 --> Dec 2019
  • ||||||||||  Fotivda (tivozanib) / EUSA Pharma, AVEO
    Clinical, Review, Journal:  Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives. (Pubmed Central) -  Jun 14, 2019   
    Nowadays, in first-line and second-line treatment of mRCC, there is an abundance of options, mainly consisting of VEGFR-directed tyrosinekinase inhibitors. This review focusses on the role of tivozanib with respect to patient selection and future perspectives in this fast-changing landscape.
  • ||||||||||  Lantus (insulin glargine) / Sanofi, Basalin (insulin glargine biosimilar) / Gan & Lee Pharma, LG Chem, Sandoz
    Enrollment open, Trial completion date:  Effects of Replacing Lantus With Basalin on the Glycemic Variation in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) -  Jun 11, 2019   
    P4,  N=100, Recruiting, 
    This review focusses on the role of tivozanib with respect to patient selection and future perspectives in this fast-changing landscape. Not yet recruiting --> Recruiting | Trial completion date: Jan 2019 --> Jul 2019
  • ||||||||||  Fotivda (tivozanib) / EUSA Pharma, AVEO
    Journal:  The role of tivozanib in advanced renal cell carcinoma therapy. (Pubmed Central) -  Apr 11, 2019   
    Here the selectivity of tivozanib may contribute to an acceptable tolerability profile when used in combination therapy. Expert Commentary: The approval of tivozanib provides an additional option for the first-line treatment of advanced or metastatic RCC patients in Europe and allows use of a VEGFR-TKI with selectivity for VEGFRs in this setting.
  • ||||||||||  ficlatuzumab (AV-299) / LG Chem
    Trial primary completion date:  Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML (clinicaltrials.gov) -  Mar 7, 2019   
    P1,  N=24, Recruiting, 
    Expert Commentary: The approval of tivozanib provides an additional option for the first-line treatment of advanced or metastatic RCC patients in Europe and allows use of a VEGFR-TKI with selectivity for VEGFRs in this setting. Trial primary completion date: Jun 2019 --> Dec 2019
  • ||||||||||  Euvax B (recombinant hepatitis B vaccine) / LG Chem
    Trial completion, Trial completion date, Trial primary completion date:  Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda (clinicaltrials.gov) -  Jan 25, 2019   
    P4,  N=132, Completed, 
    Trial primary completion date: Jun 2019 --> Dec 2019 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Apr 2017 | Trial primary completion date: Jul 2018 --> Apr 2017
  • ||||||||||  ficlatuzumab (AV-299) / LG Chem
    Biomarker, Phase classification, Enrollment change, Trial termination, Trial primary completion date, Metastases:  Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) -  Jan 3, 2019   
    P1b,  N=1, Terminated, 
    Active, not recruiting --> Completed Phase classification: P1 --> P1b | N=24 --> 1 | Suspended --> Terminated | Trial primary completion date: Jun 2018 --> Sep 2016; the investigator left the institution
  • ||||||||||  Xtandi (enzalutamide capsule) / Pfizer, Astellas, Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
    Trial completion date, Trial primary completion date, Metastases:  Tivozanib + Enzalutamide in Adv Prostate Cancer (clinicaltrials.gov) -  Dec 11, 2018   
    P2,  N=5, Active, not recruiting, 
    Phase classification: P1 --> P1b | N=24 --> 1 | Suspended --> Terminated | Trial primary completion date: Jun 2018 --> Sep 2016; the investigator left the institution Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019
  • ||||||||||  Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
    Trial completion date, Trial primary completion date, Combination therapy:  INTESTINE: Initial Combination of Gemigliptin and Metformin on Microbiota Change (clinicaltrials.gov) -  Oct 24, 2018   
    P=N/A,  N=70, Recruiting, 
    Trial completion date: Dec 2017 --> Feb 2020 | Trial primary completion date: Dec 2017 --> Mar 2019 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Apr 2019
  • ||||||||||  Hyruan (sodium hyaluronate) / LG Chem
    Enrollment open:  Intraarticular Glucose Versus Hyaluronic Acid Injection for Knee Osteoarthrosis (clinicaltrials.gov) -  Oct 11, 2018   
    P=N/A,  N=100, Recruiting, 
    Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Apr 2019 Not yet recruiting --> Recruiting
  • ||||||||||  Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
    Enrollment closed, Trial primary completion date:  Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov) -  Aug 14, 2018   
    P2,  N=28, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Aug 2020 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2018 --> Mar 2019
  • ||||||||||  Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
    Enrollment closed, Trial completion date, Combination therapy, Metastases:  TiNivo study : Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC (clinicaltrials.gov) -  Jun 26, 2018   
    P1/2,  N=28, Active, not recruiting, 
    Recruiting --> Completed | Trial primary completion date: Mar 2018 --> Dec 2017 Recruiting --> Active, not recruiting | Trial completion date: Jun 2018 --> Dec 2018
  • ||||||||||  ficlatuzumab (AV-299) / LG Chem
    Trial completion date, Trial primary completion date:  Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML (clinicaltrials.gov) -  Jun 25, 2018   
    P1,  N=24, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Jun 2018 --> Dec 2018 Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2018 --> Jun 2019
  • ||||||||||  LR19122 / LG Chem
    Trial completion:  A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults (clinicaltrials.gov) -  Apr 13, 2018   
    P1,  N=42, Completed, 
    Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2018 --> Jun 2019 Active, not recruiting --> Completed
  • ||||||||||  Euvax B (recombinant hepatitis B vaccine) / LG Chem, Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi
    Enrollment change:  Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine (clinicaltrials.gov) -  Apr 5, 2018   
    P1,  N=230, Completed, 
    Recruiting --> Completed N=350 --> 230
  • ||||||||||  Besivo (besifovir) / Gilead, LG Chem, Ildong
    Enrollment closed, Trial completion date:  Phase 3 and Extensional Study of Besifovir (clinicaltrials.gov) -  Mar 20, 2018   
    P3,  N=197, Active, not recruiting, 
    N=350 --> 230 Recruiting --> Active, not recruiting | Trial completion date: Jan 2016 --> Jan 2023